Navigation Links
NIH TRND program announces next round of drug development projects
Date:11/15/2011

This stage of drug development is called the "Valley of Death."

TRND began five pilot projects to establish the proof-of-principle and operating protocols for the program soon after it was established in 2009. Those projects include potential treatments for the neurodegenerative disease Niemann-Pick type C, the neuromuscular disorder hereditary inclusion body myopathy, the blood disorder sickle cell disease, a rare blood cancer known as chronic lymphocytic leukemia, and the parasitic worm diseases schistosomiasis and hookworm. The chronic lymphocytic leukemia and the sickle cell disease projects have recently received investigational new drug approval from the FDA and are in clinical trials.

Earlier this year, TRND approved its first four drug development projects from its initial solicitation. They focus on potential new treatments for Duchenne muscular dystrophy, a degenerative muscle disorder; fragile X syndrome, the most common inherited form of cognitive and developmental disabilities; cryptococcal meningitis, an infectious fungal disease; and core binding factor leukemia, a rare blood and bone marrow cancer.

"TRND selects projects based on their potential to move forward into human trials and transform patient care in diseases for which there is little or no therapy," said Christopher P. Austin, M.D., scientific director of the NIH Center for Translational Therapeutics, which oversees TRND and is administered by the National Human Genome Research Institute (NHGRI). "While such projects are high-risk, the scientific opportunities and medical needs are compelling. After rigorous scientific review, the new projects were selected to maximize the chance of success and to teach us important generalizable lessons about rare and neglected disease drug development."

The latest TRND projects, approved by the advisory council of the National Institute of Neurological Disorders and Stroke (NINDS) on behalf of NIH, and the collaboratin
'/>"/>

Contact: Geoffrey Spencer
spencerg@mail.nih.gov
301-451-8325
NIH/National Human Genome Research Institute
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Researchers develop new self-training gene prediction program for fungi
2. Childrens gardening programs grow environmental stewards
3. Color My Pyramid nutrition education program battles obesity in DC schools
4. Yamanaka eliminates viral vector in stem cell reprogramming
5. Salk researchers successfully reprogram keratinocytes attached to a single hair
6. Evolved Machines Selected as a Prime Contractor for DARPA Program to Engineer an Artificial Olfaction System
7. International Council for Science launches major research program on natural disasters
8. ICSU launches new program to understand the human impact on Earths life-support systems
9. SAIC Awarded $37 Million Contract to Support U.S. Army Program Executive Office - Enterprise Information Systems
10. TECNALIA leads five projects within the VII Framework Program
11. NWO and Academy launch research program with China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... birth weight and preterm birth are linked to increased ... published in the American College of Rheumatology (ACR) journal, ... birth weight and pre-term babies were not at greater ... , According to the ACR, 27 million Americans ... OA. Symptoms of OA range from mild to severe ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
... long been considered a major risk factor for cardiovascular ... risk, but the mechanisms of how arteries stave off ... the Perelman School of Medicine, University of Pennsylvania, Wistar ... that the protein apolipoprotein E (apoE) plays a major ...
... the Nowgen Schools Genomics Programme website launches with a range ... genetics in schools and colleges. , Developments in genetics research ... at a cost of $3 billion to sequencing a genome ... genetics in classroom education have remained relatively static. The pace ...
... Research led by Chu Chen, PhD, Associate Professor of Neuroscience ... enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target ... online November 1, 2012 in the Online Now section of ... that inactivation of MAGL, best known for its role in ...
Cached Biology News:Softening arteries, protecting the heart 2Softening arteries, protecting the heart 3Bridging the gap between genomics and education 2LSUHSC research identifies new therapeutic target for Alzheimer's disease 2
(Date:11/21/2014)... The California Healthcare Institute ... representing leading California academic institutions, biotechnology, medical device, ... today released a report revealing that California ... The trend shows a 4 percent increase between ... Industry Report indicates that, while biopharmaceutical and ...
(Date:11/21/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the Sodium ferrocyanide ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... month periods ended September 30, 2014.  Biorem,s complete 2014 third quarter ... ). Financial Summary:Three-months ended September 30, , ... share data) , 2014 , 2013 ... , 5,281 , 6,715 , ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring Dr. ... in the Regulatory Biology Laboratory at the Salk Institute, studies ... an “off switch” for drug resistance in cancer. , Learn ... is making a global impact in the fight against cancer. ... Cheryl K. Goodman, CEO of Social Global Mobile LLC, for ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... , COLUMBIA, Md., Sept. 8 Martek Biosciences ... of judges on the United States Court of Appeals for the ... to a patent infringement lawsuit between Martek and Lonza, Ltd., Nutrinova ... The appeals involve Lonza,s U.S. sale and use of DHA ...
... $5 Million Loan Will Leverage $15 Million ... , HARRISBURG, Pa., Sept. 8 Early-stage life ... create quality jobs with the help of a state investment in ... "The life sciences are a growth sector for Pennsylvania," ...
... Inc. (TSX: ONC, NASDAQ: ONCY ), will present ... Renshaw 11th Annual Healthcare Conference on Thursday, September 10, ... at the New York Palace Hotel from September 9 to ... will be available at: http://www.wsw.com/webcast/rrshq15/oncy or on the ...
Cached Biology Technology:Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 2Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 3PA Helping Life Science Companies Secure Venture Capital Needed to Expand, Gov. Rendell Says 2Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference 2
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
BACE (CT) rabbit polyclonal antibody...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: